Opendata, web and dolomites

HAIKU

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAIKU project word cloud

Explore the words cloud of the HAIKU project. It provides you a very rough idea of what is the project "HAIKU" about.

beds    275    patients    companies    bacteria    newly    240    therapies    resistant    13    800    prolonged    risk    care    icu    01    price    discount    negative    social    hospital    competitors    inhibitory    10    freeing    morbidity    infectivity    private    15    antimicrobial    addressable    share    pharma    preventing    created    total    families    antibodies    portfolio    complete    150    company    natural    ra    2026    resistance    class    biotech    healthcare    consist    infections    removing    public    gt    critical    jobs    molecule    14    intensive    days    protection    benefit    de    reduce    royalties    21    lives    treatment    therapy    clinical    rate    antibiotics    group    trials    curing    net    irr    units    line    worldwide    licensed    finalise    admitted    medicines    market    amr    stays    curative    therapeutics    infectious    gram    cumulative    1000    acquired    multiple    icus    develops    first    23    drug    diseases    generating    preventive    ph2    mission    remab    removal       ebitda    56    million    mortality    risked    sales   

Project "HAIKU" data sheet

The following table provides information about the project.

Coordinator
REMAB THERAPEUTICS SL 

Organization address
address: C FEIXA LLARGA SN EDIFICIO BIOPOL OFFICE 3
city: HOSPITALET DE LLOBREGAT
postcode: 8907
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://remabtx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REMAB THERAPEUTICS SL ES (HOSPITALET DE LLOBREGAT) coordinator 50˙000.00

Map

 Project objective

Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.

We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).

RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.

Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients.

RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market

By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAIKU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAIKU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More